Lexeo Therapeutics, Inc. (LXEO)

15.00 -0.46 (-2.98%) At close: 04:00PM EDT

Lexeo Therapeutics, Inc.

345 Park Avenue South
6th Floor
New York, NY 10010
United States
212-547-9879
https://www.lexeotx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 58

Key executives

Name	Title	Pay	Exercised	Year born
Mr. R. Nolan Townsend	CEO & Director	864.34k	N/A	1981
Dr. Eric Adler M.D.	Chief Medical Officer & Head of Research	623.4k	N/A	1974
Ms. Jenny R. Robertson J.D.	Chief Business & Legal Officer	617.9k	N/A	1975
Dr. Ronald G. Crystal M.D.	Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Jordan Shin M.D., Ph.D.	Senior Vice President of Clinical Development & Translational Science, Cardiology	N/A	N/A	N/A
Dr. Jordan S. Dubow M.D.	Head of CNS Clinical Development	N/A	N/A	1979
Dr. Sandi See Tai M.D.	Chief Development Officer	N/A	N/A	1971
Mr. Ryan McHenry	VP & Corporate Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Corporate governance

Lexeo Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.